{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:56:28Z","timestamp":1792281388496,"version":"4.4.0"},"reference-count":589,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["heartlungcirc.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.hlc.2018.06.1042","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T14:06:10Z","timestamp":1533132370000},"page":"1123-1208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":392,"title":["National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018"],"prefix":"10.1016","volume":"27","author":[{"given":"John J.","family":"Atherton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine G.","family":"De Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Briffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Abhayaratna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Audehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"O'Loughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cia","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2018.06.1042_bib0005","unstructured":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2011."},{"key":"10.1016\/j.hlc.2018.06.1042_bib0010","unstructured":"Grading of Recommendations A, Development and Evaluation (GRADE) Working Group. GRADE Handbook. Updated October 2013. Available at: http:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html. Accessed 21\/02\/18."},{"key":"10.1016\/j.hlc.2018.06.1042_bib0015","series-title":"Australian Medicines Handbook","year":"2018"},{"issue":"9859","key":"10.1016\/j.hlc.2018.06.1042_bib0020","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs)for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib0025","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ehj.2004.06.038","article-title":"Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure \u2013The Rotterdam Study","volume":"25","author":"Bleumink","year":"2004","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5694\/j.1326-5377.2006.tb00173.x","article-title":"Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study","volume":"184","author":"Abhayaratna","year":"2006","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12872-016-0208-4","article-title":"Prevalence of heart failure in Australia: a systematic review","volume":"16","author":"Sahle","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12913-016-1748-0","article-title":"Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue","volume":"16","author":"Chan","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2261-12-99","article-title":"Heart failure among Indigenous Australians: a systematic review","volume":"12","author":"Woods","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0050","unstructured":"Australian Bureau of Statistics. Causes of Death 2016. ABS cat. no. 3303.0, September, 2017."},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/eurjhf\/hfp029","article-title":"Understanding the \u2018epidemic of heart failure\u2019: a systematic review of trends in determinants of heart failure","volume":"11","author":"Najafi","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0065","unstructured":"Australian Institute of Health and Welfare (AIHW). Cardiovascular health compendium. Web report. Updated 22 Dec 2017. Accessed 20\/2\/18."},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5694\/mja15.00801","article-title":"Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study","volume":"204","author":"Newton","year":"2016","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/heart.89.6.615","article-title":"Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993\u20132001","volume":"89","author":"Blackledge","year":"2003","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejim.2012.11.005","article-title":"Long-term survival following acute heart failure: the Acute Heart Failure Database Main registry (AHEAD Main)","volume":"24","author":"Parenica","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1253\/circj.71.449","article-title":"Characteristics and outcomes of patients with heart failure in general practices and hospitals","volume":"71","author":"Tsutsui","year":"2007","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0090","first-page":"161","article-title":"Survival following a diagnosis of heart failure in primary care","volume":"34","author":"Taylor","year":"2017","journal-title":"Fam Pract"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/eurjhf\/hfp103","article-title":"The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis","volume":"11","author":"Somaratne","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib0105","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchf.2013.07.009","article-title":"Characterization of a novel symptom of advanced heart failure: bendopnea","volume":"2","author":"Thibodeau","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update From the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib0145","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","article-title":"Transition from chronic compensated to acute decompensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressures","volume":"118","author":"Zile","year":"2008","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib0150","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure\u2014abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0160","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/hrt.2005.084145","article-title":"Prolonged mechanical systole and increased arterial wave reflections in diastolic dysfunction","volume":"92","author":"Weber","year":"2006","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0165","doi-asserted-by":"crossref","first-page":"H1364","DOI":"10.1152\/ajpheart.00004.2014","article-title":"Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"306","author":"Kitzman","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCHEARTFAILURE.109.877720","article-title":"Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction","volume":"3","author":"Phan","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib0175","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0180","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib0185","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.115.015853","article-title":"Dose\u2013response relationship between physical activity and risk of heart failure: a meta-analysis","volume":"132","author":"Pandey","year":"2015","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0190","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.115.016801","article-title":"Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose\u2013response meta-analysis of prospective studies","volume":"133","author":"Aune","year":"2016","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib0195","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib0200","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/eurheartj\/ehu514","article-title":"Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study","volume":"36","author":"Goncalves","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCHEARTFAILURE.114.001787","article-title":"Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men","volume":"8","author":"Dorans","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ejhf.228","article-title":"Alcohol consumption and risk of heart failure: a dose\u2013response meta-analysis of prospective studies","volume":"17","author":"Larsson","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"10022","key":"10.1016\/j.hlc.2018.06.1042_bib0215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib0220","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","article-title":"The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials","volume":"36","author":"Preiss","year":"2015","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib0225","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib0230","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0235","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0240","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"9535","key":"10.1016\/j.hlc.2018.06.1042_bib0245","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0250","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0255","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0260","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study","volume":"29","author":"Vantrimpont","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0270","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0275","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0002-9149(01)02092-6","volume":"88","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0280","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"issue":"7025","key":"10.1016\/j.hlc.2018.06.1042_bib0285","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/bmj.312.7025.222","article-title":"Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction","volume":"312","author":"Davie","year":"1996","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0290","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/eurheartj\/ehi559","article-title":"What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?","volume":"27","author":"Galasko","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0300","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/hrt.2005.080150","article-title":"Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey","volume":"92","author":"Abhayaratna","year":"2006","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib0310","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0315","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/eurheartj\/eht463","article-title":"Natriuretic peptide-guided heart failure management","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0320","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib0325","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.amjcard.2004.12.032","article-title":"The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study","volume":"95","author":"Januzzi","year":"2005","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib0330","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/archinte.164.18.1978","article-title":"A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure","volume":"164","author":"Doust","year":"2004","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0335","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2003.05.011","article-title":"Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial","volume":"42","author":"Wright","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0340","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.amjcard.2004.02.012","article-title":"Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water","volume":"93","author":"Jambrik","year":"2004","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0345","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00134-012-2513-4","article-title":"International evidence-based recommendations for point-of-care lung ultrasound","volume":"38","author":"Volpicelli","year":"2012","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib0350","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1161\/CIRCULATIONAHA.110.011346","article-title":"Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology","volume":"124","author":"Assomull","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0355","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurjhf\/hfs206","article-title":"Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure","volume":"15","author":"Yoshida","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"52","key":"10.1016\/j.hlc.2018.06.1042_bib0360","first-page":"1","article-title":"Myocardial scarring on cardiovascular magnetic resonance in asymptomatic or minimally symptomatic patients with pure apical hypertrophic cardiomyopathy","volume":"14","author":"Kim","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0365","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.amjcard.2015.05.021","article-title":"Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function","volume":"116","author":"Kwong","year":"2015","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0370","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib0375","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib0380","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0385","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archinte.166.3.315","article-title":"Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department","volume":"166","author":"Januzzi","year":"2006","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0390","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-153-11-201012070-00006","article-title":"Meta-analysis. Effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting","volume":"153","author":"Lam","year":"2010","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib0395","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.0000070953.76250.B9","article-title":"B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction","volume":"107","author":"Richards","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib0400","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib0405","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.0000126825.50903.18","article-title":"Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis","volume":"109","author":"Bergler-Klein","year":"2004","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib0410","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/01.CIR.0000074039.45523.BE","article-title":"Prognostic role of brain natriuretic peptide in acute pulmonary embolism","volume":"107","author":"Kucher","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0415","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00392-016-1033-6","article-title":"Genotype\u2013phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals","volume":"106","author":"Kayvanpour","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0420","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00109-004-0589-1","article-title":"Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A\/C mutations portend a high risk of sudden death?","volume":"83","author":"van Berlo","year":"2005","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2016.09.017","article-title":"late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis","volume":"5","author":"Di Marco","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0430","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.crad.2015.05.007","article-title":"Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis","volume":"70","author":"Duan","year":"2015","journal-title":"Clin Radiol"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib0435","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/heartjnl-2015-307682","article-title":"Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis","volume":"101","author":"Briasoulis","year":"2015","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib0440","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0445","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcmg.2011.11.021","article-title":"Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy","volume":"5","author":"Green","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0450","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib0455","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","article-title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial","volume":"294","author":"Binanay","year":"2005","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib0460","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"9210","key":"10.1016\/j.hlc.2018.06.1042_bib0465","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0470","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib0475","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.10.081","article-title":"Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study","volume":"49","author":"Jourdain","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0485","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib0490","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","volume":"56","author":"Eurlings","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib0495","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","article-title":"Improved pharmacological therapy of chronic heart failure in primary care: A randomized Study of NT-proBNP Guided Management of Heart Failure\u2014SIGNAL-HF (Swedish Intervention study\u2014Guidelines and NT-proBNP AnaLysis in Heart Failure)","volume":"12","author":"Persson","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib0500","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","article-title":"The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure","volume":"17","author":"Shah","year":"2011","journal-title":"J Card Fail"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0505","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurjhf\/hfr078","article-title":"Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failurer: responders to treatment have a significantly better outcome","volume":"13","author":"Karlstrom","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0510","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinternmed.2010.35","article-title":"B-type natriuretic peptide-guided heart failure therapy: a meta-analysis","volume":"170","author":"Porapakkham","year":"2010","journal-title":"Arch Intern Med"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib0515","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib0520","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0525","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.amjcard.2006.06.017","article-title":"Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure","volume":"98","author":"Araujo","year":"2006","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0530","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/CIRCULATIONAHA.105.567727","article-title":"Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib0535","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0540","first-page":"2129","article-title":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.recesp.2015.01.003","article-title":"Pathogenesis and clinical presentation of acute heart failure","volume":"68","author":"Ponikowski","year":"2015","journal-title":"Revista espanola de cardiologia"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0550","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","article-title":"Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure","volume":"41","author":"Nohria","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0555","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0560","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ejhf.289","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0565","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"issue":"9100","key":"10.1016\/j.hlc.2018.06.1042_bib0570","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"351","author":"Cotter","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib0575","article-title":"Nitrates for acute heart failure syndromes","author":"Wakai","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0580","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","article-title":"Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods","volume":"37","author":"Mebazaa","year":"2011","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0585","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0735-1097(00)00785-3","article-title":"High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema","volume":"36","author":"Sharon","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0590","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","article-title":"Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure","volume":"153","author":"Elkayam","year":"2007","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0595","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/bja\/aev284","article-title":"The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials","volume":"115","author":"Belletti","year":"2015","journal-title":"Br J Anaesth"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0600","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib0605","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1001\/jama.294.15.1944","article-title":"Does this dyspneic patient in the emergency department have congestive heart failure?","volume":"294","author":"Wang","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0610","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0002-9343(91)80016-F","article-title":"Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: Conflicting results may lead to inappropriate care","volume":"90","author":"Chakko","year":"1991","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0615","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cardfail.2009.08.002","article-title":"Abnormal liver function in relation to hemodynamic profile in heart failure patients","volume":"16","author":"van Deursen","year":"2010","journal-title":"J Card Fail"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib0620","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","article-title":"Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE Trial","volume":"294","author":"The ESCAPE Investigators and ESCAPE Study Coordinators","year":"2005","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0625","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardio"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0630","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/hrt.2009.175257","article-title":"Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction","volume":"96","author":"Park","year":"2010","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0635","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2016-000170","article-title":"British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings","volume":"4","author":"O'Driscoll","year":"2017","journal-title":"BMJ Open Respir Res"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib0640","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/CIRCULATIONAHA.114.014494","article-title":"Air versus oxygen in ST-segment-elevation myocardial infarction","volume":"131","author":"Stub","year":"2015","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib0645","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1706222","article-title":"Oxygen therapy in suspected acute myocardial infarction","volume":"377","author":"Hofmann","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0650","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jchf.2016.03.026","article-title":"Oxygen therapy in patients with acute heart failure: friend or foe?","volume":"4","author":"Sepehrvand","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib0655","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/17482941.2011.575165","article-title":"Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes","volume":"13","author":"Iakobishvili","year":"2011","journal-title":"Acute Card Care"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0660","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/emj.2007.050419","article-title":"Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis","volume":"25","author":"Peacock","year":"2008","journal-title":"Emerg Med J"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0665","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ahj.2005.02.010","article-title":"Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative","volume":"149","author":"Meine","year":"2005","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib0670","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0002-9343(76)90565-9","article-title":"Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction","volume":"60","author":"Lee","year":"1976","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0675","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-152-9-201005040-00009","article-title":"Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema","volume":"152","author":"Weng","year":"2010","journal-title":"Ann Intern Med"},{"issue":"33","key":"10.1016\/j.hlc.2018.06.1042_bib0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13330","volume":"13","author":"Gray","year":"2009","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0685","article-title":"Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema","author":"Vital","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib0690","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/01.CCM.0000147770.20400.10","article-title":"Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema","volume":"32","author":"Park","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0695","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa0707992","article-title":"Noninvasive ventilation in acute cardiogenic pulmonary edema","volume":"359","author":"Gray","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0700","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/eurheartj\/ehi044","article-title":"Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology","volume":"26","author":"Nieminen","year":"2005","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0705","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-102-3-314","article-title":"Furosemide absorption altered in decompensated congestive heart failure","volume":"102","author":"Vasko","year":"1985","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.hlc.2018.06.1042_bib0710","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003495-199100413-00004","article-title":"Clinical pharmacology of loop diuretics","volume":"41","author":"Brater","year":"1991","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib0715","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF Randomized Clinical Trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib0720","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJM198205133061902","article-title":"Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study","volume":"306","author":"Cohn","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0725","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"TRUE-AHF Investigators. Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0730","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ejhf.830","article-title":"Serelaxin in addition to standard therapy in acute heart failure: Rationale and design of the RELAX-AHF-2 study","volume":"19","author":"Teerlink","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0735","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0733-8651(18)30462-4","article-title":"Positive inotropic\/vasodilator agents","volume":"7","author":"Colucci","year":"1989","journal-title":"Cardiol Clin"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0740","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/clc.4960160103","article-title":"Inotropic therapy of the failing myocardium","volume":"16","author":"Om","year":"1993","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0745","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0735-1097(88)92615-0","article-title":"Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope","volume":"12","author":"Packer","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib0750","doi-asserted-by":"crossref","first-page":"120G","DOI":"10.1016\/0002-9149(92)91260-B","article-title":"Current status of non-digitalis positive inotropic drugs","volume":"69","author":"Leier","year":"1992","journal-title":"Am J Cardiol"},{"issue":"5 Pt 1","key":"10.1016\/j.hlc.2018.06.1042_bib0755","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0002-8703(97)80012-9","article-title":"Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: Safety and cost efficacy","volume":"134","author":"Sindone","year":"1997","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0760","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bcpt.12385","article-title":"Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis","volume":"117","author":"Tang","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib0765","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0770","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1053\/j.jvca.2015.03.023","article-title":"Levosimendan treatment for heart failure: a systematic review and meta-analysis","volume":"29","author":"Gong","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0775","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1111\/bph.12647","article-title":"Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart","volume":"23","author":"Orstavik","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"9328","key":"10.1016\/j.hlc.2018.06.1042_bib0780","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"issue":"6 Suppl 1","key":"10.1016\/j.hlc.2018.06.1042_bib0785","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.cardfail.2006.06.284","article-title":"Levosimendan reduces length of initial hospital stay: the REVIVE II study","volume":"12","author":"Teerlink","year":"2006","journal-title":"J Card Fail"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib0790","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0795","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0733-8651(18)30126-7","article-title":"Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?","volume":"12","author":"Chatterjee","year":"1994","journal-title":"Cardiol Clin"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0800","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40256-015-0134-3","article-title":"Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0805","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.74","article-title":"Decongestion in acute heart failure","volume":"16","author":"Mentz","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0810","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mhj.2002.123144","article-title":"Diuretic resistance predicts mortality in patients with advanced heart failure","volume":"144","author":"Neuberg","year":"2002","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0815","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jacc.2005.09.014","article-title":"A new approach toward mechanical diuresis in heart failure","volume":"46","author":"Bourge","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0820","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1054\/jcaf.2003.28","article-title":"Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients","volume":"9","author":"Jaski","year":"2003","journal-title":"J Card Fail"},{"issue":"Suppl","key":"10.1016\/j.hlc.2018.06.1042_bib0825","article-title":"EUPHORIA trial: early ultrafiltration therapy in patients with decompensated heart failure and observed resistance to intervention with diuretic agents","author":"Costanzo","year":"2004","journal-title":"J Card Fail"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0830","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jacc.2005.05.098","article-title":"Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial","volume":"46","author":"Bart","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib0835","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jacc.2006.07.073","article-title":"Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure","volume":"49","author":"Costanzo","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib0840","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"10.1016\/j.hlc.2018.06.1042_bib0845","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000047398","article-title":"Clinical benefit and approach of ultrafiltration in acute heart failure","volume":"96","author":"Sharma","year":"2001","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib0850","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1751-7133.2011.00246.x","article-title":"Who has advanced heart failure? Definition and epidemiology","volume":"17","author":"AbouEzzeddine","year":"2017","journal-title":"Conges Heart Fail"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0855","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0860","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(13)61783-3","article-title":"Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial","volume":"382","author":"Thiele","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib0865","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib0870","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"Slaughter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0875","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.111.060830","article-title":"Mechanical circulatory support for advanced heart failure: Patients and technology in evolution","volume":"125","author":"Stewart","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0880","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ejcts\/ezu093","article-title":"Preoperative patient optimization using extracorporeal life support improves outcomes of INTERMACS level I patients receiving a permanent ventricular assist device","volume":"46","author":"Riebandt","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurheartj\/ehv194","article-title":"Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score","volume":"36","author":"Schmidt","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.06.1042_bib0890","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/eurheartj\/ehp292","article-title":"Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials","volume":"30","author":"Cheng","year":"2009","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joic.12080","article-title":"The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry","volume":"27","author":"O'Neill","year":"2014","journal-title":"J Interv Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib0900","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/joic.12298","article-title":"Women With cardiogenic shock derive greater benefit from early mechanical circulatory support: an update from the cVAD Registry","volume":"29","author":"Joseph","year":"2016","journal-title":"J Interv Cardiol"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib0905","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"9146","key":"10.1016\/j.hlc.2018.06.1042_bib0910","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"9169","key":"10.1016\/j.hlc.2018.06.1042_bib0915","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"issue":"9215","key":"10.1016\/j.hlc.2018.06.1042_bib0920","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib0925","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib0930","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib0935","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0940","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib0945","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib0950","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib0955","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0960","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib0965","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.1016\/j.hlc.2018.06.1042_bib0970","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.hlc.2018.06.1042_bib0975","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib0980","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib0985","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib0990","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"9744","key":"10.1016\/j.hlc.2018.06.1042_bib0995","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"issue":"9744","key":"10.1016\/j.hlc.2018.06.1042_bib1000","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib1005","article-title":"Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction","author":"Driscoll","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2016.09.001","article-title":"Improving medication titration in heart failure by embedding a structured medication titration plan","volume":"224","author":"Hickey","year":"2016","journal-title":"Int J Cardiol"},{"issue":"8875","key":"10.1016\/j.hlc.2018.06.1042_bib1015","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib1020","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib1030","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"ATLAS Study Group Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib1040","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1050","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Eichhorn","year":"2001","journal-title":"N Engl J Med"},{"issue":"9377","key":"10.1016\/j.hlc.2018.06.1042_bib1055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1060","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"MOCHA Investigators: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jchf.2012.09.002","article-title":"Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis","volume":"1","author":"Rienstra","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"9961","key":"10.1016\/j.hlc.2018.06.1042_bib1070","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib1075","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1080","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003838.pub3","article-title":"Diuretics for heart failure","author":"Faris","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"9704","key":"10.1016\/j.hlc.2018.06.1042_bib1090","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/eurjhf\/hfs127","article-title":"Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure","volume":"15","author":"Komajda","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib1100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib1110","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation G","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","article-title":"Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis","volume":"46","author":"Adams","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1130","article-title":"Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data","volume":"351","author":"Ziff","year":"2015","journal-title":"BMJ"},{"issue":"9645","key":"10.1016\/j.hlc.2018.06.1042_bib1135","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/CIRCHEARTFAILURE.115.002141","article-title":"Acute dietary nitrate intake improves muscle contractile function in patients with heart failure: a double-blind, placebo-controlled, randomized trial","volume":"8","author":"Coggan","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1145","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1152\/ajpregu.00263.2016","article-title":"Dietary nitrate supplementation and exercise tolerance in patients with heart failure with reduced ejection fraction","volume":"312","author":"Hirai","year":"2017","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.114.012957","article-title":"Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction","volume":"131","author":"Zamani","year":"2015","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.arcmed.2016.11.005","article-title":"Nutritional intervention in malnourished hospitalized patients with heart failure","volume":"47","author":"Bonilla-Palomas","year":"2016","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1160","first-page":"308","article-title":"The effect of multiple micronutrient supplementation on left ventricular ejection fraction in patients with chronic stable heart failure: a randomized, placebo-controlled trial","volume":"2","author":"McKeag","year":"2014","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/1071-9164(95)90011-X","article-title":"The Q10 Study Group. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure","volume":"1","author":"Hofman-Bang","year":"1995","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.7326\/0003-4819-132-8-200004180-00006","article-title":"The effect of coenzyme Q10 in patients with congestive heart failure","volume":"132","author":"Khatta","year":"2000","journal-title":"Ann Intern Med"},{"issue":"8 Suppl","key":"10.1016\/j.hlc.2018.06.1042_bib1175","first-page":"S134","article-title":"Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study","volume":"71","author":"Morisco","year":"1993","journal-title":"Clin Investig"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1180","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","article-title":"The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: a randomized double-blind trial","volume":"2","author":"Mortensen","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JIM.0000000000000202","article-title":"Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure","volume":"63","author":"Zhao","year":"2015","journal-title":"J Investig Med"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib1190","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ejheart.2008.10.004","article-title":"The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial","volume":"10","author":"Holubarsch","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1195","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/eurjhf\/hfp116","article-title":"Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial","volume":"11","author":"Zick","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2009.01.047","article-title":"Magnesium orotate in severe congestive heart failure (MACH)","volume":"134","author":"Stepura","year":"2009","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1205","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0002-9343(99)80349-0","article-title":"Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy","volume":"98","author":"Shimon","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1210","series-title":"DPhil Dissertation","article-title":"Effects of antioxidant on cardiovascular performance, exercise capacity, and functional status in patients with chronic heart failure","author":"Ho","year":"2007"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ajcn\/73.2.219","article-title":"A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure","volume":"73","author":"Keith","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1220","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchf.2012.11.003","article-title":"A randomized controlled trial of high dose vitamin D3 in patients with heart failure","volume":"1","author":"Boxer","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1225","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cardfail.2014.01.019","article-title":"The effect of vitamin D on aldosterone and health status in patients with heart failure","volume":"20","author":"Boxer","year":"2014","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1230","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/ajcn\/83.4.754","article-title":"Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial","volume":"83","author":"Schleithoff","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1235","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.jacc.2016.03.508","article-title":"Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE Study","volume":"67","author":"Witte","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1240","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/eurheartj\/ehx235","article-title":"Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily","volume":"38","author":"Zittermann","year":"2017","journal-title":"Eur Heart J"},{"issue":"9386","key":"10.1016\/j.hlc.2018.06.1042_bib1245","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib1250","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib1255","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1260","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib1270","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/CIRCULATIONAHA.110.940262","article-title":"Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department","volume":"122","author":"Lee","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ahj.2011.11.012","article-title":"Comparison of processes of care and clinical outcomes for patients newly hospitalized for heart failure attended by different physician specialists","volume":"163","author":"Boom","year":"2012","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1280","first-page":"1111","article-title":"Translating guidelines into clinical practice: Benefits of an acute heart failure unit","volume":"26","author":"Fonseca","year":"2007","journal-title":"Rev Port Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.acvd.2009.12.006","article-title":"Impact of heart failure management unit on heart failure-related readmission rate and mortality","volume":"103","author":"Zuily","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1290","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2261-12-81","article-title":"Effects of care pathways on the in-hospital treatment of heart failure: a systematic review","volume":"12","author":"Kul","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1295","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jhm.2054","article-title":"Project BOOST: effectiveness of a multihospital effort to reduce rehospitalization","volume":"8","author":"Hansen","year":"2013","journal-title":"J Hosp Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1300","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1377\/hlthaff.2011.0111","article-title":"An early look at a four-state initiative to reduce avoidable hospital readmissions","volume":"30","author":"Boutwell","year":"2011","journal-title":"Health Affairs"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1305","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2012.03.067","article-title":"Contemporary evidence about hospital strategies for reducing 30-day readmissions: a national study","volume":"60","author":"Bradley","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1310","unstructured":"American College of cardiology (ACC). H2H National Quality Improvement Initiative. Available at: https:\/\/cvquality.acc.org\/initiatives\/hospital-to-homeH2H. Accessed January 2018."},{"key":"10.1016\/j.hlc.2018.06.1042_bib1315","unstructured":"American Heart Association. Get With The Guidelines. Available at: http:\/\/www.heart.org\/HEARTORG\/Professional\/GetWithTheGuidelines\/Get-With-The-Guidelines---HFStroke_UCM_001099_SubHomePage.jsp. Accessed 21\/02\/18."},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1320","first-page":"810","article-title":"Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials","volume":"44","author":"McAlister","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1325","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejheart.2005.01.011","article-title":"Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse-led heart failure clinics: a meta-regression analysis","volume":"7","author":"Phillips","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1330","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ahj.2004.09.023","article-title":"Metaanalysis and review of heart failure disease management randomized controlled clinical trials","volume":"149","author":"Whellan","year":"2005","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7812\/TPP\/13-062","article-title":"Complex case conferences associated with reduced hospital admissions for high-risk patients with multiple comorbidities","volume":"18","author":"Tuso","year":"2014","journal-title":"Perm J"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1340","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamainternmed.2014.1608","article-title":"Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials","volume":"174","author":"Leppin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1345","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archinte.168.7.687","article-title":"Pharmacist care of patients with heart failure: a systematic review of randomized trials","volume":"168","author":"Koshman","year":"2008","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1350","article-title":"Structured telephone support or non-invasive telemonitoring for patients with heart failure","author":"Inglis","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1355","doi-asserted-by":"crossref","first-page":"e0118681","DOI":"10.1371\/journal.pone.0118681","article-title":"Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): a systematic review and network meta-analysis","volume":"10","author":"Kotb","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1360","unstructured":"Nursing and Midwifery Board of Australia. Nurse Practitioner Standards of Practice, 2013."},{"key":"10.1016\/j.hlc.2018.06.1042_bib1365","unstructured":"International Council of Nurses. Nurse practitioner\/advanced practice nurse: definitions and characteristics. Nursing Matters Fact Sheet 2009:3."},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib1370","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1161\/CIR.0000000000000128","volume":"130","author":"Arnett","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.03.001","article-title":"Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): a multidisciplinary position statement","volume":"212","author":"Stewart","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1380","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2014.10.087","article-title":"Heart failure and cognitive dysfunction","volume":"178","author":"Ampadu","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1385","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2017.01.153","article-title":"The prevalence of frailty in heart failure: a systematic review and meta-analysis","volume":"236","author":"Denfeld","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1390","article-title":"Frailty assessment instruments in heart failure: a systematic review","author":"McDonagh","year":"2017","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib1395","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.healun.2016.04.008","article-title":"Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation","volume":"35","author":"Jha","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1400","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jama.2010.533","article-title":"Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure","volume":"303","author":"Hernandez","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1405","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijcard.2014.04.164","article-title":"Prolonged impact of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort","volume":"174","author":"Stewart","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1410","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/archinternmed.2007.83","article-title":"Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating study evaluating outcomes of advising and counseling in heart failure (COACH)","volume":"168","author":"Jaarsma","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1415","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12872-016-0339-7","article-title":"Effects of a home-based activation intervention on self-management adherence and readmission in rural heart failure patients: the PATCH randomized controlled trial","volume":"16","author":"Young","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1420","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1474515117727740","article-title":"Self-care educational intervention to reduce hospitalisations in heart failure: a randomised controlled trial","volume":"17","author":"Boyde","year":"2018","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1425","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2318-12-70","article-title":"Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial","volume":"12","author":"Hancock","year":"2012","journal-title":"BMC Geriatr"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib1430","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.115.018006","article-title":"Do self-management interventions work in patients with heart failure? an individual patient data meta-analysis","volume":"133","author":"Jonkman","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1435","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/1474515114541729","article-title":"Isolating the benefits of fluid restriction in patients with heart failure: a pilot study","volume":"14","author":"Reilly","year":"2015","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1440","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1536\/ihj.14-288","article-title":"Liberal versus restricted fluid administration in heart failure patients. a systematic review and meta-analysis of randomized trials","volume":"56","author":"Li","year":"2015","journal-title":"Int Heart J"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib1445","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2013.552","article-title":"Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial","volume":"173","author":"Aliti","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cardfail.2012.11.007","article-title":"A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF)","volume":"19","author":"Albert","year":"2013","journal-title":"J Card Fail"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib1455","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Writing Committee","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1460","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000163","article-title":"Exercise-based rehabilitation for heart failure: systematic review and meta-analysis","author":"Sagar","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1465","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijcard.2016.07.046","article-title":"The effect of resistance training on clinical outcomes in heart failure: a systematic review and meta-analysis","volume":"221","author":"Jewiss","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1470","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCRESAHA.117.305205","article-title":"Exercise and the cardiovascular system clinical science and cardiovascular outcomes","volume":"117","author":"Lavie","year":"2015","journal-title":"Circ Res"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib1480","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"O'Connor","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1485","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchf.2017.11.016","article-title":"Addition of supervised exercise training to a post-hospital disease management program for patients recently hospitalized with acute heart failure: the EJECTION-HF randomized phase 4 trial","volume":"6","author":"Mudge","year":"2018","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1490","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/CIRCULATIONAHA.116.022924","article-title":"High-intensity interval training in patients with heart failure with reduced ejection fraction","volume":"135","author":"Ellingsen \u00d8","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1495","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2014.10.001","article-title":"Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations","volume":"57","author":"Gielen","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"46","key":"10.1016\/j.hlc.2018.06.1042_bib1500","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/eurheartj\/eht290","article-title":"An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib1505","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1510","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1515","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/heartjnl-2015-307634","article-title":"Individual patient data network meta-analysis of mortality effects of implantable cardiac devices","volume":"101","author":"Woods","year":"2015","journal-title":"Heart"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib1520","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1401426","article-title":"Survival with cardiac-resynchronization therapy in mild heart failure","volume":"370","author":"Goldenberg","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib1525","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib1530","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1535","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.amjcard.2007.06.071","article-title":"Usefulness of QRS duration to predict response to cardiac resynchronisation therapy in patients with end stage heart failure","volume":"100","author":"Molema","year":"2007","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib1540","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/01.CIR.0000118502.91105.F6","article-title":"Characterization of left ventricular activation in patients with heart failure and left bundle-branch block","volume":"109","author":"Auricchio","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1545","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCULATIONAHA.110.960898","article-title":"Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT)","volume":"123","author":"Zareba","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1550","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ahj.2011.11.014","article-title":"Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials","volume":"163","author":"Sipahi","year":"2012","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib1555","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1001\/archinternmed.2011.247","article-title":"Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials","volume":"171","author":"Sipahi","year":"2011","journal-title":"Arch Intern Med"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib1560","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/CIRCULATIONAHA.107.743120","article-title":"Results of the predictors of response to CRT (PROSPECT) trial","volume":"117","author":"Chung","year":"2008","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1565","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1570","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis","year":"2013","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.hlc.2018.06.1042_bib1575","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/eurheartj\/eht160","article-title":"Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-Year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study","volume":"34","author":"Linde","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib1580","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jacc.2012.11.051","article-title":"The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)","volume":"61","author":"Kutyifa","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1585","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1053\/euhj.2002.3232","article-title":"Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation","volume":"23","author":"Leclercq","year":"2002","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1590","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0735-1097(02)01932-0","article-title":"Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study","volume":"40","author":"Linde","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1595","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCHEARTFAILURE.112.968867","article-title":"Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the resynchronization for ambulatory heart failure trial (RAFT)","volume":"5","author":"Healey","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib1600","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/eurheartj\/ehr162","article-title":"Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial","volume":"32","author":"Brignole","year":"2011","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1605","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/europace\/eus193","article-title":"Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis","volume":"14","author":"Stavrakis","year":"2012","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1610","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1540-8167.2005.50062.x","article-title":"Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study)","volume":"16","author":"Doshi","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1615","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacc.2008.09.043","article-title":"Heart failure decompensation and all cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary?","volume":"53","author":"Koplan","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1620","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.hrthm.2011.04.015","article-title":"Cardiac resynchronisation therapy and the relationship of percent biventricular pacing to symptoms and survival","volume":"8","author":"Hayes","year":"2011","journal-title":"Heart Rhythm"},{"issue":"30","key":"10.1016\/j.hlc.2018.06.1042_bib1625","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/eurheartj\/ehv264","article-title":"Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?","volume":"36","author":"Cleland","year":"2015","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1630","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamainternmed.2014.2717","article-title":"Cardiac resynchronization therapy in women: US Food and drug administration meta-analysis of patient-level data","volume":"174","author":"Zusterzeel","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.hrthm.2011.07.038","article-title":"Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: an analysis from the COMPANION trial","volume":"9","author":"Olshansky","year":"2012","journal-title":"Heart Rhythm"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1640","first-page":"818","article-title":"The impact of the PR interval in patients receiving cardiac resynchronization therapy: results from the REVERSE Study. Focus on new insights in cardiac resynchronization","volume":"3","author":"Senfield","year":"2017","journal-title":"JACC: Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1645","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/CIRCEP.113.001299","article-title":"PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy substudy","volume":"7","author":"Kutyifa","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib1650","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/eurheartj\/ehu304","article-title":"Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study","volume":"36","author":"Kaye","year":"2015","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib1655","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1001\/jama.288.24.3115","article-title":"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial","volume":"288","author":"Wilkoff","year":"2002","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib1660","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1161\/01.CIR.0000072769.17295.B1","article-title":"Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction","volume":"107","author":"Sweeney","year":"2003","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib1665","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator Implantation in Patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1675","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib1680","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.117.028829","article-title":"Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure","volume":"136","author":"Elming","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1685","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/jce.13204","article-title":"Implantable cardioverter defibrillators for primary prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"28","author":"Stavrakis","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib1690","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/europace\/euw230","article-title":"Dual- vs: single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the defibrillateur automatique implantable-prevention primaire registry","volume":"19","author":"Defaye","year":"2017","journal-title":"Europace"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib1695","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMoa1211107","article-title":"Reduction in inappropriate therapy and mortality through ICD programming","volume":"367","author":"Moss","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1700","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacc.2007.10.061","article-title":"Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study","volume":"51","author":"Bourge","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"10017","key":"10.1016\/j.hlc.2018.06.1042_bib1705","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1710","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002600","article-title":"Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions","volume":"9","author":"Adamson","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1715","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamacardio.2017.3791","article-title":"Postmarketing adverse events related to the CardioMEMS HF System","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1720","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib1725","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1730","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003255","article-title":"Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis","volume":"10","author":"Wolff","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1735","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa0900559","article-title":"Coronary bypass surgery with or without surgical ventricular reconstruction","volume":"360","author":"Jones","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1740","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2004.07.017","article-title":"Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation","volume":"44","author":"Athanasuleas","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1745","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejcts.2008.12.046","article-title":"Wall motion score index predicts mortality and functional result after surgical ventricular restoration for advanced ischemic heart failure","volume":"35","author":"Klein","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1750","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/heartjnl-2016-310693","article-title":"Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery","volume":"103","author":"Prior","year":"2017","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1755","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0735-1097(02)01726-6","article-title":"Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis","volume":"39","author":"Allman","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1760","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa1100358","article-title":"Myocardial viability and survival in ischemic left ventricular dysfunction","volume":"364","author":"Bonow","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1765","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.0886-0440.2004.04079.x","article-title":"Update on mitral repair in dilated cardiomyopathy","volume":"19","author":"Romano","year":"2004","journal-title":"J Card Surg"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1770","first-page":"696","article-title":"A systematic review and meta-analysis of outcomes following mitral valve surgery in patients with significant functional mitral regurgitation and left ventricular dysfunction","volume":"25","author":"Andalib","year":"2016","journal-title":"J Heart Valve Dis"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1775","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1312808","article-title":"Mitral-valve repair versus replacement for severe ischemic mitral regurgitation","volume":"370","author":"Acker","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib1780","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1161\/CIRCULATIONAHA.111.072256","article-title":"Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial","volume":"125","author":"Deja","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1785","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jtcvs.2017.03.039","article-title":"Mitral valve surgery and coronary artery bypass grafting for moderate-to-severe ischemic mitral regurgitation: meta-analysis of clinical and echocardiographic outcomes","volume":"154","author":"Virk","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1790","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/mtc.2001.117277","article-title":"The double-orifice technique in mitral valve repair: a simple solution for complex problems","volume":"122","author":"Alfieri","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib1795","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.jacc.2015.10.018","article-title":"randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-Year results of EVEREST II","volume":"66","author":"Feldman","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1800","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous repair or surgery for mitral regurgitation","volume":"364","author":"Feldman","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjcard.2015.04.025","article-title":"Meta-analysis of the usefulness of Mitraclip in patients with functional mitral regurgitation","volume":"116","author":"D'Ascenzo","year":"2015","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1810","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"Bonow","year":"2008","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.hlc.2018.06.1042_bib1815","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib1820","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/01.CIR.0000038498.59829.38","article-title":"Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function","volume":"106","author":"Chaliki","year":"2002","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1825","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib1830","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib1835","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib1840","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1845","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2016.12.005","article-title":"Impact of frailty on mortality after transcatheter aortic valve implantation","volume":"185","author":"Kleczynski","year":"2017","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib1850","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/CIRCULATIONAHA.116.025630","article-title":"Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement","volume":"135","author":"Shimura","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1855","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4244\/EIJY14M08_03","article-title":"Impact of frailty on short- and long-term morbidity and mortality after transcatheter aortic valve implantation: risk assessment by Katz Index of activities of daily living","volume":"10","author":"Puls","year":"2014","journal-title":"EuroIntervention"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib1860","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/TXD.0000000000000690","article-title":"Reversibility of frailty after bridge-to-transplant ventricular assist device implantation or heart transplantation","volume":"3","author":"Jha","year":"2017","journal-title":"Transplant Direct"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1865","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.healun.2016.01.002","article-title":"First annual imacs report: a global international society for heart and lung transplantation registry for mechanical circulatory support","volume":"35","author":"Kirklin","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1870","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: special focus on framing the impact of adverse events","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1875","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1610426","article-title":"A fully magnetically levitated circulatory pump for advanced heart failure","volume":"376","author":"Mehra","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1880","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa1602954","article-title":"Intrapericardial left ventricular assist device for advanced heart failure","volume":"376","author":"Rogers","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1885","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","article-title":"Two-year outcomes with a magnetically levitated cardiac pump in heart failure","volume":"378","author":"Mehra","year":"2018","journal-title":"N Engl J Med"},{"issue":"9987","key":"10.1016\/j.hlc.2018.06.1042_bib1890","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/S0140-6736(15)60038-1","article-title":"Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series","volume":"385","author":"Dhital","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib1895","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.athoracsur.2014.06.098","article-title":"Evaluation of the organ care system in heart transplantation with an adverse donor\/recipient profile","volume":"98","author":"Zych","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib1900","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.healun.2016.08.017","article-title":"The registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report-2016; Focus theme: primary diagnostic indications for transplant","volume":"35","author":"Lund","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1910","series-title":"Australia and New Zealand Cardiothoracic Organ Transplant Registry Report","author":"Keogh","year":"2016"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1915","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjmed.2014.08.024","article-title":"Multimorbidity in heart failure: a community perspective","volume":"128","author":"Chamberlain","year":"2015","journal-title":"Am J Med"},{"issue":"10120","key":"10.1016\/j.hlc.2018.06.1042_bib1920","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib1925","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2003.11.039","article-title":"Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure","volume":"43","author":"Kalantar-Zadeh","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1930","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00392-015-0878-4","article-title":"Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study","volume":"104","author":"Lip","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib1935","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/erc.09.8","article-title":"Management of hypertension in chronic heart failure","volume":"7","author":"Manickavasagam","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib1940","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Prospective Randomized Amlodipine Survival Evaluation Study Group: effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib1945","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.96.3.856","article-title":"Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III","volume":"96","author":"Cohn","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1950","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib1955","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"6485","key":"10.1016\/j.hlc.2018.06.1042_bib1960","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/bmj.290.6485.1861","article-title":"Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin","volume":"290","author":"Bayliss","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.hlc.2018.06.1042_bib1965","series-title":"Guideline for the diagnosis and management of hypertension in adults \u2013 2016","author":"National Heart Foundation of Australia","year":"2016"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib1970","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/eurjhf\/hfs139","article-title":"Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial","volume":"15","author":"Mentz","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib1975","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.221","article-title":"Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in heart failure assessment of reduction in mortality and morbidity) programme","volume":"17","author":"Badar","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib1980","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"issue":"9645","key":"10.1016\/j.hlc.2018.06.1042_bib1985","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"6a","key":"10.1016\/j.hlc.2018.06.1042_bib1990","doi-asserted-by":"crossref","first-page":"2d","DOI":"10.1016\/S0002-9149(02)03373-8","article-title":"Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy","volume":"91","author":"Maisel","year":"2003","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib1995","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. the Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2000","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurjhf\/hfp085","article-title":"A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure","volume":"11","author":"Mamas","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FJC.0b013e31816d5f49","article-title":"Therapeutic considerations in applying rate control therapy for atrial fibrillation","volume":"52","author":"Wyse","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib2010","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib2015","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2017.08.041","article-title":"Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study","volume":"70","author":"Prabhu","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib2020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jacc.2013.01.069","article-title":"A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure","volume":"61","author":"Jones","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"issue":"46","key":"10.1016\/j.hlc.2018.06.1042_bib2030","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"issue":"9961","key":"10.1016\/j.hlc.2018.06.1042_bib2035","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.amjcard.2012.04.034","article-title":"Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure","volume":"110","author":"Chatterjee","year":"2012","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCHEARTFAILURE.115.002285","article-title":"Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry","volume":"8","author":"Li","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/HJH.0b013e3283331169","article-title":"Diabetes and incident heart failure in hypertensive and normotensive participants of the strong heart study","volume":"28","author":"de Simone","year":"2010","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cardfail.2011.09.003","article-title":"Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific)","volume":"18","author":"Atherton","year":"2012","journal-title":"J Card Fail"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib2065","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","article-title":"Prognostic implications of Type 2 diabetes mellitus in ischemic and nonischemic heart failure","volume":"68","author":"Johansson","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9982","key":"10.1016\/j.hlc.2018.06.1042_bib2070","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ejhf.455","article-title":"Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study","volume":"18","author":"Elder","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis","volume":"7","author":"Zhang","year":"2018","journal-title":"J Am Heart Assoc ."},{"key":"10.1016\/j.hlc.2018.06.1042_bib2095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2261-14-129","article-title":"The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies","volume":"14","author":"Varas-Lorenzo","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2100","doi-asserted-by":"crossref","first-page":"j2499","DOI":"10.1136\/bmj.j2499","article-title":"Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis","volume":"357","author":"Liu","year":"2017","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib2105","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2115","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2125","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.hlc.2018.06.1042_bib2130","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2135","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.hlc.2018.06.1042_bib2140","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2145","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2155","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ijo.2013.203","article-title":"The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data","volume":"38","author":"Padwal","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cjca.2014.08.004","article-title":"Obesity and the obesity paradox in heart failure","volume":"31","author":"Gupta","year":"2015","journal-title":"Can J Cardiol"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib2165","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","article-title":"Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2170","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/clc.20315","article-title":"Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure","volume":"31","author":"Ramani","year":"2008","journal-title":"Clin Cardiol"},{"issue":"10110","key":"10.1016\/j.hlc.2018.06.1042_bib2175","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(17)33039-8","article-title":"Editorial: Heart failure in an ageing population","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"5-6","key":"10.1016\/j.hlc.2018.06.1042_bib2180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF03337759","article-title":"Frequency and significance of unrecognized chronic obstructive pulmonary disease in elderly patients with stable heart failure","volume":"23","author":"Apostolovic","year":"2011","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.amjcard.2007.08.046","article-title":"Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure","volume":"101","author":"Rusinaru","year":"2008","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib2190","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","article-title":"Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists","volume":"57","author":"Hawkins","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00005344-200207000-00017","article-title":"Chronically inhaled salmeterol improves pulmonary function in heart failure","volume":"40","author":"Ng","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11897-016-0278-8","article-title":"Challenges in the management of patients with chronic obstructive pulmonary disease and heart failure with reduced ejection fraction","volume":"13","author":"Jaiswal","year":"2016","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2466-12-48","article-title":"Beta-blocker use and COPD mortality: a systematic review and meta-analysis","volume":"12","author":"Etminan","year":"2012","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1177\/030006051204000602","article-title":"Use of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials","volume":"40","author":"Ni","year":"2012","journal-title":"J Int Med Res"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib2215","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/heartjnl-2016-309458","article-title":"Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease","volume":"102","author":"Lipworth","year":"2016","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejheart.2006.08.003","article-title":"Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients","volume":"9","author":"Oldenburg","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib2225","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/eurheartj\/ehv624","article-title":"Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients","volume":"37","author":"Oldenburg","year":"2016","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib2230","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/eurheartj\/ehu522","article-title":"Sleep disordered breathing and post-discharge mortality in patients with acute heart failure","volume":"36","author":"Khayat","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2235","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001106.pub2","article-title":"Continuous positive airways pressure for obstructive sleep apnoea in adults","author":"Giles","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib2240","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa051001","article-title":"Continuous positive airway pressure for central sleep apnea and heart failure","volume":"353","author":"Bradley","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2245","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062298","article-title":"Impact of continuous positive airway pressure treatment on left ventricular ejection fraction in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials","volume":"8","author":"Sun","year":"2013","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2255","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/hrt.73.3.237","article-title":"Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure","volume":"73","author":"Walsh","year":"1995","journal-title":"Br Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2265","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1378\/chest.06-0919","article-title":"Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure","volume":"131","author":"Tamura","year":"2007","journal-title":"Chest"},{"issue":"10048","key":"10.1016\/j.hlc.2018.06.1042_bib2270","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(16)30961-8","article-title":"Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial","volume":"388","author":"Costanzo","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2275","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jsr.12097","article-title":"Are we missing a simple treatment for most adult sleep apnea patients? The avoidance of the supine sleep position","volume":"23","author":"Oksenberg","year":"2014","journal-title":"J Sleep Res"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2280","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cardfail.2015.06.004","article-title":"Effect of semirecumbent sleep position on severity of obstructive sleep apnea in patients with heart failure","volume":"21","author":"Basoglu","year":"2015","journal-title":"J Card Fail"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2285","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/ejhf.410","article-title":"Differential impact of body position on the severity of disordered breathing in heart failure patients with obstructive vs. central sleep apnoea","volume":"17","author":"Pinna","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1164\/rccm.200507-1035OC","article-title":"Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study","volume":"173","author":"Javaheri","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2295","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000282","article-title":"Gout and the risk for incident heart failure and systolic dysfunction","volume":"2","author":"Krishnan","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2016.12.004","article-title":"Allopurinol as a therapeutic option in cardiovascular disease","volume":"172","author":"Okafor","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib2305","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2310","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejheart.2008.07.013","article-title":"D.L.S. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials","volume":"10","author":"Scott","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib2320","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib2325","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2330","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.160.6.777","article-title":"Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem","volume":"160","author":"Page","year":"2000","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","article-title":"Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results","volume":"5","author":"Meinert","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2340","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","article-title":"Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial","volume":"2","author":"Bertagnolli","year":"2009","journal-title":"Cancer Prev Res Phila"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2345","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti\u2013tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2350","doi-asserted-by":"crossref","first-page":"17C","DOI":"10.1016\/j.amjcard.2005.03.008","article-title":"Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches","volume":"95","author":"Gullestad","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2355","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2006.06.055","article-title":"Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes","volume":"48","author":"Rutledge","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2360","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ejhf.133","article-title":"Symptoms of anxiety and depression and risk of heart failure: the HUNT study","volume":"16","author":"Gustad","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2365","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1388-9842(02)00101-0","article-title":"Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure","volume":"4","author":"Faris","year":"2002","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.hlc.2018.06.1042_bib2370","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.190769","volume":"118","author":"Lichtman","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2375","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1001\/jamainternmed.2015.5220","article-title":"Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial","volume":"175","author":"Freedland","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2380","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-017-9640-5","article-title":"Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis","author":"Jeyanantham","year":"2017","journal-title":"Heart Fail Rev"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib2385","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2010.03.068","article-title":"Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial","volume":"56","author":"O'Connor","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hlc.2018.06.1042_bib2390","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1001\/jama.2016.7635","article-title":"Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial","volume":"315","author":"Angermann","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2395","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ejhf.101","article-title":"Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Tu","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2400","series-title":"Vitamin and Mineral Nutrition Information System (VMNIS)","article-title":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity","author":"World Health Organization","year":"2011"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2405","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2410","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2420","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ahj.2009.10.015","article-title":"Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure","volume":"158","author":"Adams","year":"2009","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2425","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjcard.2008.05.058","article-title":"Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions","volume":"102","author":"Abramov","year":"2008","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2430","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ahj.2011.02.013","article-title":"Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials","volume":"161","author":"Kotecha","year":"2011","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.hlc.2018.06.1042_bib2435","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2440","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib2445","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2450","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib2455","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2460","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.pcad.2015.11.007","article-title":"Targeting iron deficiency anemia in heart failure","volume":"58","author":"Saraon","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"issue":"19","key":"10.1016\/j.hlc.2018.06.1042_bib2465","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2470","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ehf2.12006","article-title":"Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib2475","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/jnci\/djq366","article-title":"Improved estimates of cancer-specific survival rates from population-based data","volume":"102","author":"Howlader","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009584","article-title":"Declining death rates reflect progress against cancer","volume":"5","author":"Jemal","year":"2010","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib2485","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2490","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology. An update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib2495","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2500","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/jobm.201200302","article-title":"Regulation of daunorubicin biosynthesis in Streptomyces peucetius \u2013feed forward and feedback transcriptional control","volume":"53","author":"Vasanthakumar","year":"2013","journal-title":"J Basic Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.hlc.2018.06.1042_bib2505","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mgme.2000.3043","article-title":"Molecular basis of anthracycline-induced cardiotoxicity and its prevention","volume":"71","author":"Horenstein","year":"2000","journal-title":"Mol Genet Metab"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2510","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2515","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7150\/ijbs.6058","article-title":"Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity","volume":"9","author":"McCaffrey","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2520","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","article-title":"Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function","volume":"121","author":"De Angelis","year":"2010","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.hlc.2018.06.1042_bib2525","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.hlc.2018.06.1042_bib2530","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1681.2009.05323.x","article-title":"Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress","volume":"37","author":"Ma","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"4 Suppl 3","key":"10.1016\/j.hlc.2018.06.1042_bib2545","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2550","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2555","first-page":"169","article-title":"Cyclophosphamide cardiac injury mimicking acute myocardial infarction","volume":"12","author":"Dow","year":"1993","journal-title":"Bone marrow transplant"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2560","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2565","first-page":"446","article-title":"Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?","volume":"8","author":"Lenneman","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2570","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2575","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cjca.2016.01.027","article-title":"Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond","volume":"32","author":"Moudgil","year":"2016","journal-title":"Can J Cardiol"},{"issue":"9544","key":"10.1016\/j.hlc.2018.06.1042_bib2580","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.hlc.2018.06.1042_bib2585","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2590","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/01.HYP.0000215207.54689.31","article-title":"Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload","volume":"47","author":"Izumiya","year":"2006","journal-title":"Hypertension"},{"issue":"9604","key":"10.1016\/j.hlc.2018.06.1042_bib2595","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2600","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2605","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib2610","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib2615","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2620","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2625","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2630","article-title":"Heart failure following blood cancer therapy in pediatric and adult populations","author":"Franzon","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2635","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5306\/wjco.v5.i3.529","article-title":"Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines","volume":"5","author":"Crozier","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib2640","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2645","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11936-014-0313-6","article-title":"Cardiac complications of chemotherapy: Role of biomarkers","volume":"16","author":"Colombo","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2650","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"issue":"25 Pt A","key":"10.1016\/j.hlc.2018.06.1042_bib2655","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"AJ Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.hlc.2018.06.1042_bib2660","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175544","article-title":"Anthracyclines induce early changes in left ventricular systolic and diastolic function: a single centre study","volume":"12","author":"Boyd","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2670","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2675","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review","volume":"6","author":"Thavendiranathan","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2680","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCIMAGING.109.918540","article-title":"Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model","volume":"3","author":"Lightfoot","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2685","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1067\/mhj.2001.115436","article-title":"Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging\u2014a pilot study","volume":"141","author":"Wassmuth","year":"2001","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2690","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","volume":"7","author":"Jordan","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2695","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1139\/y94-022","article-title":"Early incidence of adriamycin treatment on cardiac parameters in the rat","volume":"72","author":"Cottin","year":"1994","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2700","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib2705","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cardfail.2013.07.007","article-title":"Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice","volume":"19","author":"Ammon","year":"2013","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2710","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2715","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2720","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2725","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Mostafavi Toroghi","year":"2016","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2730","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.hlc.2018.06.1042_bib2735","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2740","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2745","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2750","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate","volume":"2","author":"Dessi","year":"2013","journal-title":"Springerplus"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2755","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2760","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hlc.2018.06.1042_bib2765","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib2770","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2775","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2780","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cardfail.2014.04.013","article-title":"Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis","volume":"20","author":"Hopper","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2785","unstructured":"Austroads Assessing Fitness to Drive for commercial and private vehicledrivers (2016). Medical standards for licensing and clinical management guidelines \u2212A resource for health professionals in Australia. As amended up to August 2017. Available at: https:\/\/www.onlinepublications.austroads.com.au\/items\/AP-G56-17. Accessed 22\/2\/18."},{"issue":"5","key":"10.1016\/j.hlc.2018.06.1042_bib2790","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/eurjhf\/hft003","article-title":"Effects of reducing inspired oxygen concentration for one hour in patients with chronic heart failure: implications for air travel","volume":"15","author":"Hobkirk","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 2","key":"10.1016\/j.hlc.2018.06.1042_bib2795","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/hrt.2010.203091","article-title":"Fitness to fly for passengers with cardiovascular disease","volume":"96","author":"Smith","year":"2010","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2800","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10741-017-9614-7","article-title":"Influenza infection and heart failure-vaccination may change heart failure prognosis?","volume":"22","author":"Kadoglou","year":"2017","journal-title":"Heart Fail Rev"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2805","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1089\/jpm.2016.0476","article-title":"Gender differences in sexual interest or activity among adults with symptomatic heart failure","volume":"20","author":"Fischer","year":"2017","journal-title":"J Palliat Med"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2810","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIR.0b013e3182447787","article-title":"Sexual activity and cardiovascular disease: A scientific statement from the American Heart Association","volume":"125","author":"Levine","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2815","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ehf2.12108","article-title":"Sexual function of patients with heart failure: Facts and numbers","volume":"4","author":"Jaarsma","year":"2017","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2820","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jacc.2009.08.036","article-title":"Pregnancy outcomes in women with dilated cardiomyopathy","volume":"55","author":"Grewal","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2018.06.1042_bib2825","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/eurheartj\/ehr218","article-title":"ESC guidelines on the management of cardiovascular diseases during pregnancy","volume":"32","author":"(ESC) ESoC","year":"2011","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.hlc.2018.06.1042_bib2830","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM200105243442101","article-title":"Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy","volume":"344","author":"Elkayam","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2835","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1161\/CIRCULATIONAHA.111.070607","article-title":"Contraception in patients with heart failure","volume":"126","author":"Sedlak","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hlc.2018.06.1042_bib2840","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cardfail.2017.04.003","article-title":"Heart failure and thermoregulatory control: can patients with heart failure handle the heat?","volume":"23","author":"Balmain","year":"2017","journal-title":"J Card Fail"},{"issue":"11\u201312","key":"10.1016\/j.hlc.2018.06.1042_bib2845","doi-asserted-by":"crossref","first-page":"662","DOI":"10.5694\/j.1326-5377.2007.tb01466.x","article-title":"Morbidity and mortality during heatwaves in metropolitan Adelaide","volume":"187","author":"Nitschke","year":"2007","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.hlc.2018.06.1042_bib2850","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejheart.2008.03.008","article-title":"Hot summers and heart failure: seasonal variations in morbidity and mortality in Australian heart failure patients (1994\u20132005)","volume":"10","author":"Inglis","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2018.06.1042_bib2855","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCHEARTFAILURE.112.967299","article-title":"Habitual coffee consumption and risk of heart failure: a dose\u2013response meta-analysis","volume":"5","author":"Mostofsky","year":"2012","journal-title":"Circulation Heart Fail"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2860","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2013.06.035","article-title":"Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality","volume":"62","author":"O'Keefe","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccl.2013.09.009","article-title":"Epidemiology of heart failure and scope of the problem","volume":"32","author":"Liu","year":"2014","journal-title":"Cardiol Clin"},{"issue":"12","key":"10.1016\/j.hlc.2018.06.1042_bib2870","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cardfail.2012.10.019","article-title":"Examining the effects of an outpatient palliative care consultation on symptom burden, depression, and quality of life in patients with symptomatic heart failure","volume":"18","author":"Evangelista","year":"2012","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2875","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCN.0b013e318239f629","article-title":"Upstreaming palliative care for patients with heart failure","volume":"27","author":"Buck","year":"2012","journal-title":"J Cardiovasc Nurs"},{"issue":"25","key":"10.1016\/j.hlc.2018.06.1042_bib2880","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1161\/CIRCULATIONAHA.109.869123","article-title":"Palliative care in the treatment of advanced heart failure","volume":"120","author":"Adler","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2885","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cardfail.2013.01.011","article-title":"Palliative care consultations for heart failure patients: how many, when, and why?","volume":"19","author":"Bakitas","year":"2013","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2890","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/01621424.2014.995257","article-title":"A comparison between end-of-life home care clients with cancer and heart failure in Ontario","volume":"34","author":"Fernandes","year":"2015","journal-title":"Home Health Care Serv Q"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2895","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/jpm.2013.0658","article-title":"Palliative care referral among patients hospitalized with advanced heart failure","volume":"17","author":"Greener","year":"2014","journal-title":"J Palliat Med"},{"issue":"20","key":"10.1016\/j.hlc.2018.06.1042_bib2900","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2016.16840","article-title":"Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis","volume":"316","author":"Kavalieratos","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hlc.2018.06.1042_bib2905","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ejhf.151","article-title":"Effects of person-centred and integrated chronic heart failure and palliative home care: PREFER: a randomized controlled study","volume":"16","author":"Brannstrom","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2018.06.1042_bib2910","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacc.2017.05.030","article-title":"Palliative care in heart failure: the PAL-HF Randomized, Controlled Clinical Trial","volume":"70","author":"Rogers","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2018.06.1042_bib2915","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/jpm.2014.0192","article-title":"Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial","volume":"18","author":"Sidebottom","year":"2015","journal-title":"J Palliat Med"},{"issue":"14","key":"10.1016\/j.hlc.2018.06.1042_bib2920","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/heartjnl-2015-308638","article-title":"Effects of a transitional palliative care model on patients with end-stage heart failure: a randomised controlled trial","volume":"102","author":"Wong","year":"2016","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.hlc.2018.06.1042_bib2925","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1532-5415.2007.01234.x","article-title":"Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care","volume":"55","author":"Brumley","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.hlc.2018.06.1042_bib2930","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/jpm.2016.0330","article-title":"Palliative Care Interventions for Patients with Heart Failure: a Systematic Review and Meta-Analysis","volume":"20","author":"Diop","year":"2017","journal-title":"J Palliat Med"},{"issue":"15","key":"10.1016\/j.hlc.2018.06.1042_bib2935","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/CIRCULATIONAHA.110.989632","article-title":"Associations between outpatient heart failure process-of-care measures and mortality","volume":"123","author":"Fonarow","year":"2011","journal-title":"Circulation"},{"issue":"243","key":"10.1016\/j.hlc.2018.06.1042_bib2940","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitor and beta-blocker in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hlc.2018.06.1042_bib2945","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618317773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618317773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T16:01:44Z","timestamp":1661702504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950618317773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":589,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1443950618317773"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Heart Foundation of Australia. Published by Elsevier B.V. on behalf of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}